CATX Stock Analysis: Perspective Therapeutics | NYSE MKT
Medical Devices | NYSE MKT, USA | Market Cap: 361m USD | 12M Return: -6.6% | US46489V3024 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.15M
Qual. Beats: 0
Rev. Trend: -97.8%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Perspective Therapeutics, Inc. (NYSE MKT: CATX) is a Seattle-based radiopharmaceutical company developing precision targeted alpha therapies (TAT) for cancer treatment in the United States. Founded in 2004 and formerly known as Isoray, Inc., the company rebranded in February 2022 to reflect its strategic focus on alpha-emitting radiopharmaceuticals, a specialized oncology modality distinct from conventional chemotherapy and external beam radiation.
The companys clinical pipeline includes VMT-a-NET (Phase 1/2a for SSTR2-expressing neuroendocrine tumors), VMT01 (Phase 1/2a for MC1R-positive metastatic melanoma), and PSV359, an alpha therapy targeting fibroblast activation protein alpha. Perspective also develops Pluvicto, a beta-emitting radioligand therapy for PSMA-positive metastatic castration-resistant prostate cancer. The company has a clinical trial collaboration with Bristol Myers Squibb to evaluate VMT01 in combination with nivolumab for melanoma patients.
As a small-cap healthcare company, Perspective operates within the radiopharmaceutical sector, which combines targeted molecular biology with medical isotopes to deliver radiation selectively to cancer cells. Targeted alpha therapies represent a frontier in this field, as alpha particles deliver high-energy radiation over a very short range, potentially limiting damage to surrounding healthy tissue compared to beta-emitting agents.
- VMT01 Phase 1/2a melanoma data readout could shift outlook
- Novartis dominates with Lutathera and Pluvicto beta therapies
- Cash burn raises dilution risk as trials expand
| Net Income: -116.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.31 > 0.02 and ΔFCF/TA 6.03 > 1.0 |
| NWC/Revenue: 50.1k% < 20% (prev 14.8k%; Δ 35.3k% < -1%) |
| CFO/TA -0.24 > 3% & CFO -93.1m > Net Income -116.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.61 > 1.5 & < 3 |
| Outstanding Shares: last quarter (73.8m) vs 12m ago 4.45% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.12% > 50% (prev 0.40%; Δ -0.28% > 0%) |
| Interest Coverage Ratio: -291.8 > 6 (EBIT TTM -89.0m / Interest Expense TTM 305k) |
| A: 0.52 (Total Current Assets 241.5m - Total Current Liabilities 36.5m) / Total Assets 392.0m |
| B: -0.99 (Retained Earnings -387.8m / Total Assets 392.0m) |
| C: -0.25 (EBIT TTM -89.0m / Avg Total Assets 351.4m) |
| D: 4.75 (Book Value of Equity 323.9m / Total Liabilities 68.2m) |
| Altman-Z'' = 3.49 = A |
| DSRI: 3.0 (Receivables 269k/225k, Revenue 409k/1.24m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.64 (AQ_t 0.10 / AQ_t-1 0.16) |
| SGI: 0.33 (Revenue 409k / 1.24m) |
| TATA: -0.06 (NI -116.4m - CFO -93.1m) / TA 392.0m) |
| Beneish M = -2.08 (Cap -4..+1) = BB |
As of September 03, 2026, the stock is trading at USD 3.10 with a total of 864,616 shares traded. Over the past week, the price has changed by -1.90%, over one month by +2.99%, over three months by -13.89% and over the past year by -6.63%.
Current recommended Stop Loss: 2.60 (which is 16.1% or 2.9 ATR below the current price).
Perspective Therapeutics has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy CATX.
- StrongBuy: 10
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12.5 | 304.2% |
P/E Forward = 25.7069
P/S = 887.5362
P/B = 1.1138
Revenue TTM = 409k USD
EBIT TTM = -89.0m USD
EBITDA TTM = -87.2m USD
Long Term Debt = 1.57m USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.15m USD (from shortTermDebt, last quarter)
Debt = 6.58m USD (from shortLongTermDebtTotal, last quarter) + Leases 2.62m
Net Debt = -230.3m USD (calculated: Debt 6.58m - CCE 236.9m)
Enterprise Value = 130.4m USD (360.7m + Debt 6.58m - CCE 236.9m)
Interest Coverage Ratio = -291.8 (Ebit TTM -89.0m / Interest Expense TTM 305k)
EV/FCF = -1.08x (Enterprise Value 130.4m / FCF TTM -121.2m)
FCF Yield = -92.92% (FCF TTM -121.2m / Enterprise Value 130.4m)
FCF Margin = -29.6k% (FCF TTM -121.2m / Revenue TTM 409k)
Net Margin = -28.5k% (Net Income TTM -116.4m / Revenue TTM 409k)
Gross Margin = unknown ((Revenue TTM 409k - Cost of Revenue TTM 4.04m) / Revenue TTM)
Tobins Q-Ratio = 0.33 (Enterprise Value 130.4m / Total Assets 392.0m)
Interest Expense / Debt = 4.63% (Interest Expense 305k / Debt 6.58m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -70.3m (EBIT -89.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.61 (Total Current Assets 241.5m / Total Current Liabilities 36.5m)
Debt / Equity = 0.02 (Debt 6.58m / totalStockholderEquity, last quarter 323.9m)
Debt / EBITDA = 2.64 (negative EBITDA) (Net Debt -230.3m / EBITDA -87.2m)
Debt / FCF = 1.90 (negative FCF - burning cash) (Net Debt -230.3m / FCF TTM -121.2m)
Total Stockholder Equity = 280.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.14% (Net Income -116.4m / Total Assets 392.0m)
RoE = -41.56% (Net Income TTM -116.4m / Total Stockholder Equity 280.1m)
RoCE = -31.59% (EBIT -89.0m / Capital Employed (Equity 280.1m + L.T.Debt 1.57m))
RoIC = -19.72% (negative operating profit) (NOPAT -70.3m / Invested Capital 356.6m)
WACC = 7.59% (E(360.7m)/V(367.3m) * Re(7.66%) + D(6.58m)/V(367.3m) * Rd(4.63%) * (1-Tc(0.21)))
Discount Rate = 7.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 72.83 | Cagr: 19.42%
[DCF] Fair Price = unknown (Cash Flow -121.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.42 | # QB: 0
Revenue Correlation: -97.78 | Revenue CAGR: -61.27% | SUE: -0.08 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.23 | Chg30d=+22.87% | Revisions=+25% | Analysts=5
EPS current Year (2026-12-31): EPS=-0.99 | Chg30d=+11.81% | Revisions=+25% | GrowthEPS=+29.4% | GrowthRev=-63.1%
EPS next Year (2027-12-31): EPS=-1.02 | Chg30d=+10.07% | Revisions=+0% | GrowthEPS=-2.8% | GrowthRev=+12.3%
[Analyst] Revisions Ratio: +22% (up=4, down=2)